

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Patel Snehal			2. Issuer Name and Ticker or Trading Symbol Greenwich LifeSciences, Inc. [GLSI]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CEO and CFO		
(Last) (First) (Middle) C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR., BUILDING 14			3. Date of Earliest Transaction (Month/Day/Year) 09/29/2020					
(Street) STAFFORD, TX 77477			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/29/2020		M		176,448	A	(6)	1,040,131	D	
Common Stock	09/29/2020		M		13,736	A	(7)	1,053,867	D	
Common Stock	09/29/2020		M		10,394	A	(8)	1,064,261	D	
Common Stock	09/29/2020		M		103,911	A	(9)	1,168,172	D	
Common Stock	09/29/2020		M		1,144,529	A	(6)	1,321,327	I	see footnote (1)
Common Stock	09/29/2020		M		2,997	A	(7)	1,324,324	I	see footnote (1)
Common Stock	09/29/2020		M		33,708	A	(8)	1,358,032	I	see footnote (1)
Common Stock	09/29/2020		M		50,001	A	(9)	1,408,033	I	see footnote (1)
Common Stock	09/29/2020		M		76,780	A	(7)	76,780	I	see footnote (2)
Common Stock	09/29/2020		M		52,620	A	(9)	129,400	I	see footnote (2)
Common Stock								2,405,670	I	see footnote (3)
Common Stock								1,320,226	I	see footnote (4)
Common Stock								1,329,590	I	see footnote (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Series A Preferred Stock	(6)	09/29/2020		M		176,448	(6)	(6)	Common Stock	176,448	\$ 0	0	D	
Series A Preferred Stock	(6)	09/29/2020		M		1,144,529	(6)	(6)	Common Stock	1,144,529	\$ 0	0	I	see footnote (1)
Series B Preferred Stock	(7)	09/29/2020		M		13,736	(7)	(7)	Common Stock	13,736	\$ 0	0	D	
Series B Preferred Stock	(7)	09/29/2020		M		76,780	(7)	(7)	Common Stock	76,780	\$ 0	0	I	see footnote (2)
Series B Preferred Stock	(7)	09/29/2020		M		2,997	(7)	(7)	Common Stock	2,997	\$ 0	0	I	see footnote (1)
Series C Preferred Stock	(8)	09/29/2020		M		10,394	(8)	(8)	Common Stock	10,394	\$ 0	0	D	
Series C Preferred Stock	(8)	09/29/2020		M		33,708	(8)	(8)	Common Stock	33,708	\$ 0	0	I	see footnote (1)
Series D Preferred Stock	(9)	09/29/2020		M		89,510	(9)	(9)	Common Stock	89,510	\$ 0	0	D	
Series D Preferred Stock	(9)	09/29/2020		M		45,328	(9)	(9)	Common Stock	45,328	\$ 0	0	I	see footnote (2)
Series D Preferred Stock	(9)	09/29/2020		M		43,072	(9)	(9)	Common Stock	43,072	\$ 0	0	I	see footnote (1)
Series D Preferred Stock	(10)	09/29/2020		J(11)	14,401		(10)	(10)	Common Stock	14,401	\$ 0	14,401	D	
Series D Preferred Stock	(10)	09/29/2020		J(11)	6,929		(10)	(10)	Common Stock	6,929	\$ 0	6,929	I	see footnote (1)
Series D Preferred Stock	(10)	09/29/2020		J(11)	7,292		(10)	(10)	Common Stock	7,292	\$ 0	7,292	I	see footnote (2)
Series D Preferred Stock	(9)	09/29/2020		M		14,401	(9)	(9)	Common Stock	14,401	\$ 0	0	D	
Series D Preferred Stock	(9)	09/29/2020		M		6,929	(9)	(9)	Common Stock	6,929	\$ 0	0	I	see footnote (1)
Series D Preferred Stock	(9)	09/29/2020		M		7,292	(9)	(9)	Common Stock	7,292	\$ 0	0	I	see footnote (2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Patel Snehal C/O GREENWICH LIFESCIENCES, INC. 3992 BLUEBONNET DR., BUILDING 14 STAFFORD, TX 77477	X		CEO and CFO	

Signatures

/s/ Snehal Patel	09/30/2020
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The securities are owned by Snehal Patel IRA. Snehal Patel is the Trustee of Snehal Patel IRA, and in such capacity is deemed to hold voting and dispositive power over the securities held by such IRA.
- (2) Kinnary Patel is the spouse of Snehal Patel and Trustee of the Kinnary Patel IRA.
- (3) The securities are owned by Patel Family Trust 1. Snehal Patel, as co-Trustee of Patel Family Trust 1, shares voting and dispositive power over the securities held by such trust with his spouse.
- (4) The securities are owned by Patel Family Trust 2. Snehal Patel, as co-Trustee of Patel Family Trust 2, shares voting and dispositive power over the securities held by such trust with his spouse.
- (5) The securities are owned by Patel Family Trust 3. Snehal Patel, as co-Trustee of Patel Family Trust 3, shares voting and dispositive power over the securities held by such trust with his spouse.
- (6) The Series A Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- (7) The Series B Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- (8) The Series C Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- (9) The Series D Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
The Series D Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no
- (10) additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Issuer's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation").
- (11) The Reporting Person was issued additional shares of Series D Preferred Stock in connection with the Issuer's initial public offering as a result of the anti-dilution protection provisions set forth in the Issuer's Certificate of Incorporation.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.